Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 232

1.

Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition.

de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J.

Ther Drug Monit. 2004 Apr;26(2):137-44. Review.

PMID:
15228154
2.
3.
4.

Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics.

Farré M, Abanades S, Roset PN, Peiró AM, Torrens M, O'Mathúna B, Segura M, de la Torre R.

J Pharmacol Exp Ther. 2007 Dec;323(3):954-62. Epub 2007 Sep 21.

5.

Cardiovascular and sympathetic responses and reflex changes elicited by MDMA.

O'Cain PA, Hletko SB, Ogden BA, Varner KJ.

Physiol Behav. 2000 Jul 1-15;70(1-2):141-8.

PMID:
10978489
6.

MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.

Verrico CD, Miller GM, Madras BK.

Psychopharmacology (Berl). 2007 Jan;189(4):489-503. Epub 2005 Oct 12.

PMID:
16220332
7.

Clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): the influence of gender and genetics (CYP2D6, COMT, 5-HTT).

Pardo-Lozano R, Farré M, Yubero-Lahoz S, O'Mathúna B, Torrens M, Mustata C, Pérez-Mañá C, Langohr K, Cuyàs E, Carbó Ml, de la Torre R.

PLoS One. 2012;7(10):e47599. doi: 10.1371/journal.pone.0047599. Epub 2012 Oct 24.

8.

Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").

McNamara R, Kerans A, O'Neill B, Harkin A.

Neuropharmacology. 2006 Jan;50(1):69-80. Epub 2005 Sep 26.

PMID:
16188283
9.

Enhancement of 3,4-methylenedioxymethamphetamine neurotoxicity by the energy inhibitor malonate.

Nixdorf WL, Burrows KB, Gudelsky GA, Yamamoto BK.

J Neurochem. 2001 Apr;77(2):647-54.

10.

Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy").

Green AR, Cross AJ, Goodwin GM.

Psychopharmacology (Berl). 1995 Jun;119(3):247-60. Review.

PMID:
7675958
11.
12.

Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.

Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R.

J Clin Psychopharmacol. 2000 Aug;20(4):455-66.

PMID:
10917407
13.

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI.

Pharmacol Rev. 2003 Sep;55(3):463-508. Epub 2003 Jul 17. Review.

14.

[A case of acute psychotic episode after a single dose of ecstasy].

Vaiva G, Bailly D, Boss V, Thomas P, Lestavel P, Goudemand M.

Encephale. 2001 Mar-Apr;27(2):198-202. French.

PMID:
11407274
16.

The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans.

O'Mathúna B, Farré M, Rostami-Hodjegan A, Yang J, Cuyàs E, Torrens M, Pardo R, Abanades S, Maluf S, Tucker GT, de la Torre R.

J Clin Psychopharmacol. 2008 Oct;28(5):523-9. doi: 10.1097/JCP.0b013e318184ff6e.

PMID:
18794647
17.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
18.

Mechanisms mediating the ability of caffeine to influence MDMA ('Ecstasy')-induced hyperthermia in rats.

Vanattou-Saïfoudine N, McNamara R, Harkin A.

Br J Pharmacol. 2010 Jun;160(4):860-77. doi: 10.1111/j.1476-5381.2010.00660.x.

19.

Supplemental Content

Support Center